Clinical Trials Register

Summary
EudraCT Number:	2016-001399-31
Sponsor's Protocol Code Number:	GS-US-412-2055
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2016-09-26
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2016-001399-31

A.3

Full title of the trial

A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection

Estudio de fase 3, aleatorizado y doble ciego para evaluar la seguridad y la eficacia de la combinación de dosis fijas de emtricitabina y tenofovir alafenamida (F/TAF) una vez al día como profilaxis previa a la exposición en varones y mujeres transexuales que mantienen relaciones sexuales con varones y tienen riesgo de infección por VIH-1

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A study to compare the safety and effectiveness of F/TAF vs F/TDF (Truvada) once daily for the prevention of HIV, in men and transgender women who have sex with men and are at risk of HIV infection

Estudio para comparar la seguridad y efectividad de F/TAF frente a F/TDF (Truvada) una vez al día para la prevención de VIH, en hombres y mujeres transexuales que mantienen relaciones sexuales con hombres y tienen riesgo de infección por VIH

A.4.1

Sponsor's protocol code number

GS-US-412-2055

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Gilead Sciences, Inc.
B.1.3.4	Country	United States
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Gilead Sciences, Inc.
B.4.2	Country	United States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Gilead Sciences International Ltd.
B.5.2	Functional name of contact point	Clinical Trials Mailbox
B.5.3	Address:
B.5.3.1	Street Address	Flowers Building, Granta Park
B.5.3.2	Town/ city	Abington, Cambridge
B.5.3.3	Post code	CB21 6GT
B.5.3.4	Country	United Kingdom
B.5.4	Telephone number	+34913789830
B.5.5	Fax number	+441223897284
B.5.6	E-mail	clinical.trials@gilead.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.2	Product code	F/TAF
D.3.4	Pharmaceutical form	Film-coated tablet
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	EMTRICITABINE
D.3.9.1	CAS number	143491-57-0
D.3.9.2	Current sponsor code	F
D.3.9.4	EV Substance Code	SUB01882MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	200
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	TENOFOVIR ALAFENAMIDE
D.3.9.1	CAS number	379270-37-8
D.3.9.2	Current sponsor code	TAF
D.3.9.4	EV Substance Code	SUB121761
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	25
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Truvada
D.2.1.1.2	Name of the Marketing Authorisation holder	Gilead Sciences International Limited
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.2	Product code	F/TDF
D.3.4	Pharmaceutical form	Film-coated tablet
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	EMTRICITABINE
D.3.9.1	CAS number	143491-57-0
D.3.9.2	Current sponsor code	F
D.3.9.4	EV Substance Code	SUB01882MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	200
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	TENOFOVIR DISOPROXIL FUMARATE
D.3.9.1	CAS number	202138-50-9
D.3.9.2	Current sponsor code	TDF
D.3.9.4	EV Substance Code	SUB12607MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	300
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Film-coated tablet
D.8.4	Route of administration of the placebo	Oral use
D.8 Placebo: 2
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Film-coated tablet
D.8.4	Route of administration of the placebo	Oral use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Healthy volunteers (Pre-exposure prophylaxis (PrEP) of human immunodeficiency virus 1 (HIV-1))

Voluntarios sanos (Profilaxis previa a la exposición (PrEP) de virus de inmunodeficiencia humana 1 (VIH-1))

E.1.1.1

Medical condition in easily understood language

Prevention of HIV

Prevención de VIH

E.1.1.2

Therapeutic area

Diseases [C] - Virus Diseases [C02]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	19.0
E.1.2	Level	LLT
E.1.2	Classification code	10073527
E.1.2	Term	HIV pre-exposure prophylaxis
E.1.2	System Organ Class	100000004865

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

The primary objective of this study is:
- To assess the rates of HIV-1 seroconversion in men (MSM) and transgender women (TGW) who have sex with men who are administered daily F/TAF or F/TDF with a minimum follow-up of 48 weeks and at least 50% of subjects have 96 weeks of follow-up

El objetivo principal del estudio es:

- Evaluar las tasas de seroconversión del VIH-1 en varones homosexuales y mujeres transexuales (MTS) que mantengan relaciones sexuales con varones que reciban F/TAF o F/TDF a diario con un seguimiento mínimo de 48 semanas y que al menos el 50% de los sujetos sean objeto de seguimiento durante 96 semanas.

E.2.2

Secondary objectives of the trial

The secondary objectives of this study are:
- To compare bone safety between the treatments as determined by dual energy x-ray absorptiometry (DXA) tests of hip and spine bone mineral density (BMD) in a subset of participants at Week 48 and Week 96 in the blinded phase
- To compare renal safety between the treatments as determined by urine retinol-binding protein (RBP) to creatinine ratio, urine beta-2-microglobulin to creatinine ratio, urine protein to creatinine ratio (UPCR), and serum creatinine at Week 48 and
Week 96 in the blinded phase
- To assess the rates of HIV-1 seroconversion in men (MSM) and transgender women (TGW) who have sex with men who are administered daily F/TAF or F/TDF at the end of blinded phase
- To compare the general safety between the treatments

Further exploratory endpoints are included as per the protocol.

Los objetivos secundarios de este estudio son:
- Comparar la seguridad ósea entre los tratamientos conforme a lo determinado mediante la densidad mineral ósea (DMO) en la columna vertebral y la cadera en un subgrupo de participantes evaluados mediante absorciometría radiológica de doble energía (DEXA) en la semana 48 y la semana 96 de la fase enmascarada.
- Comparar la seguridad renal entre los tratamientos conforme a lo determinado mediante el cociente entre proteína fijadora de retinol (RBP) y creatinina en orina, el cociente entre β-2-microglobulina y creatinina en orina y el cociente entre proteínas y creatinina en orina (CACO), así como mediante la creatinina sérica en la semana 48 y en la semana 96 de la fase enmascarada.
- Evaluar las tasas de seroconversión del VIH-1 en varones homosexuales y MTS que mantengan relaciones sexuales con varones que reciban F/TAF o F/TDF a diario al final de la fase enmascarada.
- Comparar la seguridad general entre los tratamientos.

E.2.3

Trial contains a sub-study

Yes

E.2.3.1

Full title, date and version of each sub-study and their related objectives

- A DXA substudy will be performed in a subset of approximately 400 subjects at a subset of sites (excluding Germany).

During the blinded phase of the study, all substudy subjects will have DXA scan of the hip and spine at Day 1, Week 48 and Week 96. Substudy subjects in Treatment Arm 2 (F/TDF) will have an additional scan at the Unblinding Visit which will serve as a baseline for the open-label phase. All substudy subjects will have a scan at OL Week 48.

- Se realizarán DEXA cada 48 semanas durante todo el estudio en un subgrupo de aproximadamente 400 sujetos en un subgrupo de centros (salvo Alemania).

Durante la fase enmascarada del estudio, todos los pacientes del sub-estudio se realizarán DEXA en la cadera y la columna vertebral en el Día 1, Semana 48 y Semana 96. Los pacientes del sub- estudio en el brazo 2 de tratamiento (F/TDF) se realizarán un escáner adicional en la visita de desenmascaramiento que servirá como base para la fase abierta. Todos los pacientes del sub-estudio se realizarán un escáner en la semana 48 de la fase abierta.

E.3

Principal inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
1) HIV-1 negative status
2) MSM or TGW (male at birth) who have at least one of the following:
a) condomless anal intercourse with at least two unique male partners in the past 12 weeks (partners must be either HIV-infected or of unknown HIV status)
b) documented history of syphilis in the past 24 weeks
c) documented history of rectal gonorrhea or chlamydia in the past 24 weeks
3) Age ≥ 18 years
4) Estimated GFR ≥ 60 mL/min according to the Cockcroft-Gault formula for creatinine clearance
5) Adequate liver and hematologic function
6) Willing and able to comply with study procedures

Los pacientes deben cumplir todos los siguientes criterios de inclusión para ser elegibles para la participación en este estudio:

- Ausencia de infección por el VIH-1.
- Varones homosexuales o MTS (varones de nacimiento) que cumplan algo de lo siguiente:
a) sexo anal sin preservativo con al menos dos parejas masculinas únicas en las 12 semanas precedentes (parejas infectadas con el VIH o cuyo estado en relación con el VIH es desconocido)
b) antecedentes conocidos de sífilis en las 24 semanas precedentes
c) antecedentes conocidos de gonococia rectal o clamidia en las 24 semanas precedentes

- Edad ≥ 18 años.
- Filtración glomerular estimada ≥ 60 ml/min según la fórmula de Cockcroft-Gault.
- Función hepática y hematológica adecuada.
- Voluntad y capacidad para cumplir los procedimientos del estudio.

E.4

Principal exclusion criteria

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) Known hypersensitivity to the IMP, the metabolites, or formulation excipient
2) Have a suspected or known active, serious infection(s)
3) Acute viral hepatitis or evidence of chronic hepatitis B infection. Subjects found to be susceptible to HBV infection should be referred for HBV vaccination
4) Evidence or known history of hepatitis C infection
5) Need for continued use of any contraindicated concomitant medications
6) Have an implanted defibrillator or pacemaker
7) Have a history of osteoporosis or bone fragility fractures
8) Current alcohol or substance abuse judged by the Investigator to be problematic such that it potentially interferes with subject study compliance
9) Grade 3 or Grade 4 proteinuria or glycosuria that is unexplained or not clinically manageable
10) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements
11) In the 30 days prior to screening have received F/TDF or any other approved or investigational agent for the prevention of HIV-1 infection or during the trial would be receiving any other approved or investigational agents for the treatment/prevention of HIV-1 infection
12) Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial

No podrán participar en este estudio los sujetos que cumplan alguno de los criterios de exclusión siguientes.
1) Hipersensibilidad conocida al PEI, sus metabolitos o los excipientes de la formulación.
2) Sospecha o presencia confirmada de infección grave activa.
3) Hepatitis vírica aguda o indicios de infección crónica por el virus de la hepatitis B. Los sujetos considerados sensibles a la infección por el VHB serán derivados para que se les administre la vacuna contra el VHB.
4) Indicios o antecedentes conocidos de hepatitis C.
5) Necesidad de seguir utilizando algún medicamento concomitante contraindicado.
6) Presencia de un desfibrilador o marcapasos implantado.
7) Antecedentes de osteoporosis o de fracturas óseas por fragilidad.
8) Abuso actual de alcohol o de sustancias que, según el criterio del investigador, es problemático hasta el punto de que podría afectar al cumplimiento del estudio.
9) Proteinuria o glucosuria de grado 3 o de grado 4 sin explicación o que no pueden tratarse clínicamente.
10) Cualquier otra afección clínica o tratamiento previo que, en opinión del investigador, haga que el sujeto no sea adecuado para el estudio o no sea capaz de cumplir los requisitos de administración.
11) En los 30 días anteriores a la selección, haber recibido T/FDT o cualquier otro fármaco aprobado o experimental para la prevención de la infección por el VIH-1 o previsión de recibir durante el ensayo cualquier otro fármaco aprobado o experimental para el tratamiento/prevención de la infección por el VIH-1.
12) Durante la participación en este estudio queda prohibida la participación en cualquier otro ensayo clínico (incluidos ensayos observacionales) sin la aprobación previa del promotor.

E.5 End points

E.5.1

Primary end point(s)

The primary endpoint will be the incidence of seroconversions per 100 PY as defined by the HIV-1 RNA by PCR when the last subject has a minimum of 48 weeks of follow-up and 50% of the subjects have at least 96 weeks of follow-up after randomization.

El criterio de valoración principal será la tasa de seroconversión en 100 años-persona (A-P)definido por el ARN del VIH-1 detectado mediante una reacción en cadena de la polimerasa (PCR). El análisis principal tendrá lugar cuando el último sujeto lleve un mínimo de 48 semanas en seguimiento y al menos el 50 % de los sujetos lleven al menos 96 semanas en seguimiento desde la aleatorización.

E.5.1.1

Timepoint(s) of evaluation of this end point

When the last subject has a minimum of 48 weeks of follow-up and 50% of the subjects have at least 96 weeks of follow-up after randomization

Cuando el último sujeto lleve un mínimo de 48 semanas en seguimiento y al menos el 50 % de los sujetos lleven al menos 96 semanas en seguimiento desde la aleatorización.

E.5.2

Secondary end point(s)

The key (α-controlled) secondary endpoints in the blinded phase are:
- The percent change from baseline in hip BMD at Week 48 in a subset of subjects
- The percent change from baseline in spine BMD at Week 48 in a subset of subjects
- The percent change from baseline in renal biomarkers of urine RBP to creatinine ratio, beta-2-microglobulin to creatinine ratio, and UPCR at Week 48
- The change from baseline in serum creatinine at Week 48

Other secondary endpoints include:
- The incidence of seroconversions per 100 PY as defined by the HIV RNA-1 by PCR at the end of the blinded phase
- The percent change from baseline in hip and spine BMD at Week 96 in the blinded phase in a subset of subjects
- The percent change from baseline in renal biomarkers of urine RBP to creatinine ratio, urine beta-2-microglobulin to creatinine ratio, and UPCR at Week 96 in the blinded phase
- The change from baseline in serum creatinine at Week 96 in the blinded phase
- The incidence of treatment-emergent adverse events and laboratory toxicities

Los criterios de valoración secundarios más importantes (control α) en la fase enmascarada son:
• Variación porcentual de la DMO de la cadera entre el momento basal y la semana 48 en un subgrupo de participantes.
• Variación porcentual de la DMO de la columna entre el momento basal y la semana 48 en un subgrupo de participantes.
• Variación porcentual de los biomarcadores renales del cociente entre RBP y creatinina en orina, beta2-microglobulina y creatinina y CACO entre el momento basal y la semana 48.
• Variación de la creatinina sérica entre el momento basal y la semana 48.
Otros criterios de valoración secundarios son:
• Incidencia de seroconversiones por 100 AP, definida por el ARN del VIH-1 determinado mediante PCR, al final de la fase enmascarada.
• Variación porcentual de la DMO de la cadera y la columna entre el momento basal y la semana 96 de la fase enmascarada en un subgrupo de participantes.
• Variación porcentual de los biomarcadores renales del cociente entre RBP y creatinina en orina, beta2-microglobulina y creatinina en orina y CACO entre el momento basal y la semana 96 de la fase enmascarada
• Variación de la creatinina sérica entre el momento basal y la semana 96 de la fase enmascarada
• Incidencia de acontecimientos adversos y alteraciones analíticas surgidos durante el tratamiento.

E.5.2.1

Timepoint(s) of evaluation of this end point

Week 48 and Week 96

Semana 48 y Semana 96

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

Yes

E.6.3

Therapy

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

Yes

E.8.2.2

Placebo

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Austria

Canada

Denmark

France

Germany

Ireland

Netherlands

Spain

United Kingdom

United States

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

Última visita del último paciente

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

4900

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

100

F.2 Gender

F.2.1

Female

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

Yes

F.3.2

Patients

F.3.3

Specific vulnerable populations

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

250

F.4.2

For a multinational trial

F.4.2.1

In the EEA

2000

F.4.2.2

In the whole clinical trial

5000

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

Subjects will be healthy volunteers so will not require ongoing treatment. If a subject tests positive for HIV-1 during the trial, they will be referred to their local healthcare provider for appropriate treatment, and long-term care will remain the responsibility of their primary treating physician.
Subjects in countries where F/TAF is not commercially available at end of OL Week 48 will be able to continue F/TAF until it is commercially available, or until Gilead terminates development.

Los pacientes serán voluntarios sanos que no requieran tratamiento. Si un paciente da positivo para VIH-1 durante el estudio, será referido a su centro de salud local para recibir el tratamiento adecuado, la atención a largo plazo será responsabilidad de su médico de atención primaria.
Los pacientes de países donde F/TAF no este comercializado al final de la semana 48 de la fase abierta, podrán continuar con F/TAF hasta que esté comercializado, o hasta que Gilead finalice el desarrollo.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2016-11-21

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2016-10-06

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials